American biochemist Dr. Kary B. Mullis won the 1993 Nobel Prize for chemistry for revolutionizing the fields of biology and medicine with his method for producing abundant fragments of deoxyribonucleic acid (DNA). His Polymerase Chain Reaction (PCR) enables scientists to create sequences of genetic material in quantities that are large enough to study. PCR has played a major role in the International Human Genome Project, which has major health and antiaging implications. The technique has also become invaluable in disease diagnosis, forensic-science analysis in convicting the guilty and freeing the falsely accused, and the study of DNA from ancient or fossil tissues. In 1998 Mullis was inducted into the National Inventors Hall of Fame in the United States.

Dr. Kary B. Mullis  received his Ph.D. degree from the University of California, Berkeley, in 1973. After postdoctoral work at the University of Kansas Medical School, he joined California's Cetus Corporation as a research scientist in 1979. Dr. Kary B. Mullis  made his discovery while working at Cetus in 1983 and when Cetus closed in 1991, Hoffman-La Roche purchased the PCR patent for $300 million. In 1986 Mullis became director of molecular biology at Xytronyx Inc., a plastics manufacturer in San Diego, California. Since 1988 he has worked as an independent consultant for various firms, such as Angenics, Cytometrics, Eastman Kodak, Abbott Labs, Milligen / Biosearch and Specialty Laboratories. He currently is Vice President of Burstein Technologies Co.